MedTrace Logo

Combination Therapy for Alcohol Use Disorder

NCT07249554 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2026-05-12

No results posted yet for this study

Summary

This human laboratory study will collect preliminary safety and efficacy data from a sample of participants enrolled in a 4-week in-patient treatment program for alcohol use disorder.

Conditions

Interventions

DRUG

Placebo

Over-encapsulated non-active microcrystalline cellulose

DRUG

Glucagon-Like Peptide-1 Agonist (GLP-1)

Over-encapsulated Glucagon-Like Peptide-1 Agonist (GLP-1) oral tablets

DRUG

Naltrexone (oral tablets)

Over-encapsulated Naltrexone (oral tablets)

Sponsors & Collaborators

Principal Investigators

  • Andrew S. Huhn, Ph.D. · Johns Hopkins University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-31
Primary Completion
2028-07-31
Completion
2028-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07249554 on ClinicalTrials.gov